Related Experiment Video

Updated: May 10, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Genetic modification of hypertension by sGCα1

Patrick Y Sips1, Emmanuel S Buys

  • 1Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Thier 511B, Boston, MA 02114.

Trends in Cardiovascular Medicine
|June 13, 2013
PubMed

Insights

Soluble guanylate cyclase (sGC) plays a key role in blood pressure regulation. This review explores how nitric oxide (NO)-cGMP signaling and genetic factors influence hypertension, using mouse models and human genetic studies.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Biology
  • Human Genetics

Background:

  • Hypertension is a major risk factor for cardiovascular diseases, with undefined molecular and genetic underpinnings.
  • Nitric oxide (NO) and soluble guanylate cyclase (sGC) are critical in blood pressure regulation.
  • Understanding NO-cGMP signaling is crucial for hypertension research.

Purpose of the Study:

  • To review the role of sGC in blood pressure regulation.
  • To discuss insights from genetically modified mouse models and human genetic studies.
  • To elucidate the mechanisms of NO-cGMP signaling in hypertension pathogenesis.

Main Methods:

  • Review of existing literature on sGC and blood pressure.
  • Analysis of data from genetically modified mouse models of hypertension.
  • Examination of human genetic studies, including genome-wide association studies (GWAS).

Main Results:

  • sGC is integral to the NO-cGMP pathway regulating blood pressure.
  • Genetic variations identified through GWAS influence blood pressure and hypertension susceptibility.
  • Mouse models provide mechanistic insights into sGC function in hypertension.

Conclusions:

  • sGC is a critical target for understanding and potentially treating hypertension.
  • Integrating findings from animal models and human genetics advances hypertension research.
  • Further investigation into NO-cGMP signaling and genetic factors is warranted.

More Related Videos

Assessing Murine Resistance Artery Function Using Pressure Myography07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
What is Genetic Engineering?00:49

What is Genetic Engineering?

Overview